Hasil Pencarian - Boulos Haraoui

  • Menampilkan 1 - 15 hasil dari 15
Perbaiki Hasil
  1. 1
    Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study

    Real-World Tocilizumab Use in Patients with Rheumatoid Arthritis in Canada: 12-Month Results From an Observational, Noninterventional Study oleh Boulos Haraoui, Shahin Jamal, Vandana Ahluwalia, Diana Fung, Tarang Manchanda, Majed Khraishi

    Diterbitkan 2018-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept

    Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept oleh Louis Bessette, Boulos Haraoui, Emmanouil Rampakakis, Joanna Dembowy, Marc-Olivier Trépanier, Janet Pope

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry

    Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinic... oleh Denis Choquette, Louis Bessette, Evo Alemao, Boulos Haraoui, Roelien Postema, Jean-Pierre Raynauld, Louis Coupal

    Diterbitkan 2019-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment

    Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment oleh Jeffrey R. Curtis, Kevin Winthrop, Cathy O’Brien, Matladi N. Ndlovu, Marc de Longueville, Boulos Haraoui

    Diterbitkan 2017-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Tocilizumab Patterns of Use, Effectiveness, and Safety in Patients with Rheumatoid Arthritis: Final Results from a Set of Multi-National Non-Interventional Studies

    Tocilizumab Patterns of Use, Effectiveness, and Safety in Patients with Rheumatoid Arthritis: Final Results from a Set of Multi-National Non-Interventional Studies oleh Boulos Haraoui, Gustavo Casado, László Czirják, Andrew Taylor, Lingli Dong, Peter Button, Yves Luder, Roberto Caporali

    Diterbitkan 2019-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate

    Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate oleh Roy Fleischmann, Boulos Haraoui, Maya H. Buch, David Gold, Gosford Sawyerr, Harry Shi, Annette Diehl, Kristen Lee

    Diterbitkan 2022-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study

    Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study oleh Andrea Rubbert-Roth, Koji Kato, Boulos Haraoui, Maureen Rischmueller, Yanxi Liu, Nasser Khan, Heidi S. Camp, Ricardo M. Xavier

    Diterbitkan 2024-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years

    Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years oleh Janet E. Pope, Edward Keystone, Shahin Jamal, Lisy Wang, Lara Fallon, John Woolcott, Irina Lazariciu, Douglass Chapman, Boulos Haraoui

    Diterbitkan 2019-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Once-Daily, Controlled-Release Tramadol and Sustained-Release Diclofenac Relieve Chronic Pain due to Osteoarthritis: A Randomized Controlled Trial

    Once-Daily, Controlled-Release Tramadol and Sustained-Release Diclofenac Relieve Chronic Pain due to Osteoarthritis: A Randomized Controlled Trial oleh André D Beaulieu, Paul M Peloso, Boulos Haraoui, William Bensen, Glen Thomson, John Wade, Patricia Quigley, John Eisenhoffer, Zoltan Harsanyi, Andrew C Darke

    Diterbitkan 2008-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index

    Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index oleh Vivian P. Bykerk, Andrew Blauvelt, Jeffrey R. Curtis, Cécile Gaujoux‐Viala, Tore K. Kvien, Kevin Winthrop, Nicola Tilt, Christina Popova, Xavier Mariette, Boulos Haraoui

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study

    Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study oleh Louis Bessette, Boulos Haraoui, Andrew Chow, Isabelle Fortin, Sanjay Dixit, Majed Khraishi, Derek Haaland, Sami Elmoufti, Fabienne Staelens, Irina Bogatyreva, Jerry Syrotuik, Saeed Shaikh

    Diterbitkan 2019-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift)

    Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b... oleh Boulos Haraoui, Janet Pope, Edward C Keystone, Eduardo Mysler, Tatjana Lukic, Harry Shi, Stanley B Cohen, Rebecca Germino, Lori Stockert, Annette Diehl, Sujatha Menon, Shixue Liu

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry

    Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry oleh Proton Rahman, Philip Baer, Ed Keystone, Denis Choquette, Carter Thorne, Boulos Haraoui, Andrew Chow, Rafat Faraawi, Wojciech Olszynski, John Kelsall, Emmanouil Rampakakis, Allen J. Lehman, Francois Nantel

    Diterbitkan 2020-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    A Bridge Too Far? Real‐World Practice Patterns of Early Glucocorticoid Use in the Canadian Early Arthritis Cohort

    A Bridge Too Far? Real‐World Practice Patterns of Early Glucocorticoid Use in the Canadian Early Arthritis Cohort oleh Kathleen M. Andersen, Orit Schieir, Marie‐France Valois, Susan J. Bartlett, Louis Bessette, Gilles Boire, Boulos Haraoui, Glen Hazlewood, Carol Hitchon, Edward C. Keystone, Janet Pope, Diane Tin, J Carter Throne, Vivian P. Bykerk, CATCH Investigators

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH).

    Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH). oleh Cheryl Barnabe, Ye Sun, Gilles Boire, Carol A Hitchon, Boulos Haraoui, J Carter Thorne, Diane Tin, Désirée van der Heijde, Jeffrey R Curtis, Shahin Jamal, Janet E Pope, Edward C Keystone, Susan Bartlett, Vivian P Bykerk, CATCH Investigators

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: